The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Current strategies in extending half-lives of therapeutic proteins
Abstract
ABSTRACT Macromolecular protein and peptide therapeutics have been proven to be effective in treating critical human diseases precisely. Thanks to biotechnological advancement, a huge number of proteins and peptide therapeutics were made their way to pharmaceutical market in past few decades. However, one of the biggest challenges to be addressed for protein therapeutics during clinical application is their fast degradation in serum and quick elimination owing to enzymatic degradation, renal clearance, liver metabolism and immunogenicity, attributing to the short half‐lives. Size and hydrophobicity of protein molecules make them prone to kidney filtration and liver metabolism. On the other hand, proteasomes responsible for protein destruction possess the capability of specifically recognizing almost all kinds of foreign proteins while avoiding any unwanted destruction of cellular components. At present almost all protein‐based drug formulations available in market are administered intravenously (IV) or subcutaneously (SC) with high dosing at frequent interval, eventually creating dose‐fluctuation‐related complications and reducing patient compliance vastly. Therefore, artificially increasing the therapeutic half‐life of a protein by attaching to it a molecule that increases the overall size (eg, PEG) or helps with receptor mediated recycling (eg, albumin), or manipulating amino acid chain in a way that makes it more prone towards aggregate formation, are some of the revolutionary approaches to avoid the fast degradation in vivo. Half‐life extension technologies that are capable of dramatically enhancing half‐lives of proteins in circulation (2–100 folds) and thus improving their overall pharmacokinetic (PK) parameters have been successfully applied on a wide range of protein therapeutics from hormones and enzymes, growth factor, clotting factor to interferon. The focus of the review is to assess the technological advancements made so far in enhancing circulatory half‐lives and improving therapeutic potency of proteins. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Production of recombinant proteins by microbes and higher organisms
Demain, A. L., & Vaishnav, P. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.01.008 · Cited by 1,028
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Zarychanski, R., Abou-Setta, A. M., Turgeon, A. F., Houston, B. L., McIntyre, L., Marshall, J. C., & Fergusson, D. A. (2013) · JAMA · doi:10.1001/jama.2013.430 · Cited by 649
(2012) · Choice Reviews Online · doi:10.5860/choice.49-6264 · Cited by 578
Cited by
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
Yin, H., Zhou, X., Huang, Y.-H., King, G. J., Collins, B. M., Gao, Y., Craik, D. J., & Wang, C. K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08132 · Cited by 57
Metadata
- Authors
- Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 301
- Pages
- 176-189
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2920526722
- Cited by
- 278
- References
- 79
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current strategies in extending half-lives of therapeutic proteins. https://app.cochat.ai/papers/10.1016/j.jconrel.2019.02.016
- The paper
- Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H. (2019). Current strategies in extending half-lives of therapeutic proteins. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2019.02.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.